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Abstract
Background:  Mucin glycoprotein's are major components of mucus and are considered an
important class of tumor associated antigens. The objective of this study was to investigate the
expression of human MUC  genes (MUC1,  MUC2,  MUC5B,  MUC5AC and MUC8) in human
endometrium and cervix, and to compare and quantitate the expression of MUC genes in normal
and cancerous tissues.
Methods: Slot blot techniques were used to study the MUC gene expression and quantitation.
Results: Of the five-mucin genes studied, MUC1, MUC5B and MUC8 showed high expression levels
in the normal and cancerous endometrial and cervical tissues, MUC2  and  MUC5AC  showed
considerably lower expression. Statistically, higher levels of MUC1,  MUC5B  and  MUC8  were
observed in endometrial adenocarcinomas compared to normal tissues. In contrast, only MUC1
levels increased with no significant changes in expression of MUC5B and MUC8 in cervical tumors
over normal cervical tissues.
Conclusion: Endometrial tumors showed increased expression of MUC1, MUC5B and MUC8 over
normal tissues. Only MUC1 appears to be increase, in cervical tumors. All the studied tissues
showed high and consistent expression of MUC8 mRNA. Low to neglible levels of MUC2 and
MUC5AC were observed in all studied endometrial and cervical tissues.
Background
Mucins are high molecular weight glycoprotein compo-
nents of mucus (> 250 kDa), which protect and lubricate
the epithelial surfaces of the respiratory, gastrointestinal
and reproductive tracts in the body [1]. Mucins are heavily
glycosylated (40–80%) and the oligosaccharides are
attached through O-glycosidic linkages to the hydroxyl
group of serine and threonine in the protein backbone
[2,3]. The striking feature of nearly all mucin genes iso-
lated thus far is the presence of repeat sequences that are
either tandem in nature as in the case of MUC1 [4] or
slightly imperfect repeats as in the case of MUC8 [5]. In
general, the repeats are found in the central portion of the
protein backbone, which are flanked by unique regions.
Mucins have been classified as either membrane-bound or
secretory depending on the presence of a putative trans-
membrane region.
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Altered mucin secretions and/or MUC  gene expression
patterns have been implicated in several cancerous condi-
tions, such as gastric carcinomas [6-10], colorectal carci-
nomas [11-13], breast cancers [14-16] esophageal
carcinomas [17], pancreatic tumors [18-20] and lung ade-
nocarcinomas [21-23]. Accordingly, studies have also
been conducted to determine the expression of MUC
genes in human reproductive tissues and to investigate
their possible altered quantitative and/or qualitative
expression in cancerous conditions. Serial analysis of gene
expression of ovarian cell lines and tissues indicated that
among other genes, MUC1 is up-regulated in cancerous
conditions [24]. Another study also showed that the
expression of MUC1 correlated with poor prognosis in
ovarian carcinoma [25]. Normal endocervical epithelium
was found to express MUC genes 1, 4, 5AC, 5B, and 6, with
relatively weak expression of MUC2. Normal endocervical
and vaginal epithelium expresses MUC genes 1 and 4 and
endometrial epithelium expresses MUC1  and  MUC6
[26,27]. In an earlier report, we demonstrated the anti-
genic similarities between respiratory and reproductive
tract mucins using a variety of mucin antibodies [28]. In
another study, we reported the antigenic cross reactivity of
human tracheal mucin with male and female reproductive
tissues expressing MUC8 mRNA[29]. While these reports,
in general, indicate the manifestation of a variety of MUC
genes in reproductive tissues, information regarding
mucin gene expression in corresponding tumor tissues is
still lacking.
According to The American Cancer Society's Cancer Facts
and Figures, it is estimated that there will be 12,200 new
cases of invasive cervical cancer (uterine cervix) and
40,100 new cases of endometrial cancer (uterine corpus)
that will be diagnosed this year. Hence, a better under-
standing of MUC  gene expression patterns in female
reproductive malignancies would help enhance prognosis
and therapy. To contribute towards this purpose, we
investigated the expression of five mucin genes (MUC1,
MUC2, MUC5AC, MUC5B and MUC8) in normal repro-
ductive and cancerous tissues.
Methods
Human tissues
Normal and malignant endometrium and cervical tissues
were obtained from Co-operative Human Tissue Network
(CHTN, Birmingham, AL) and National Disease Research
Interchange (NDRI, Philadelphia, PA). Malignant tissues
with over 95 percent tumor content were selected for the
study. The nomenclature adopted for the tissues was as
follows: endometrial adenocarcinomas (EA), normal
endometrium (EN), cervical carcinomas (CA), normal
Table 1: Primers, annealing temperatures and accession numbers for MUC genes
Gene Acc. # Primers A.temp
MUC5AC AF015521 S-GTGGAACCACGATGACAGC 60°C
AS-TCAGCACATAGCTGCAGTCG
MUC5B Y09788 S-TGCAATCAGCACTGTGACATTGAC 60°C
AS-TTCTCCAGGGTCCAGGTCTCATTC
MUC8 U14383 S-GTTCAGGTCTCCTGCCGG 57°C
AS-CGAGGCGCCATCATGGAC
Acc. # are obtained from GenBank provided by National Center for Biotechnology Information, Bethesda, MD.
Table 2: Tissue classification of endometrial (EA) and cervical 
(CA) carcinomas.
Tissue Age Grade Differentiation
EA1 44 II wd
EA2 47 II md
EA3 50 I wd
EA4 48 III pd
EA5 38 III pd
EA6 53 I-II md
EA7 45 III wd
EA8 54 I md
EA9 58 II md
EA10 44 III md
EA11 36 I wd
EA12 50 II md
EA13 31 I md
CA1 30 IB md
CA2 35 IB pd
CA3 48 IB pd
CA4 39 IB md
CA5 63 III pd
CA6 46 II wd
CA7 57 II md
CA8 40 IIB pd
CA9 33 I md
CA10 42 I pd
CA11 52 I-II wd
CA12 31 II pd
CA13 47 II md
pd-poorly differentiated, md-moderately differentiated and wd-well 
differentiatedBMC Cancer 2005, 5:124 http://www.biomedcentral.com/1471-2407/5/124
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cervix (CX). These tissues were acquired on dry ice and
kept frozen at -80°C until use. The classification of
tumors was performed according to the International Fed-
eration of Gynecology and Obstetrics (FIGO) as indicated
in Table 2.
The normal tissues EN (mean age: 41, median age: 43)
and CX (mean age: 43, median age: 44) used in the study
were obtained by hysterectomy for benign gynecological
disorders. The menstrual cycle of all the patients with nor-
mal tissues were in early to late proliferative phases,
except for EN3, EN4, EN10, CX3, CX4 and CX13 were in
late secretory phase. The provided pathology reports of
both normal and tumor tissues indicated no inflamma-
tion or infections.
Total RNA isolation
Total RNA was extracted from frozen tissues using the TRI-
zol reagent (Life Technologies) according to manufac-
turer's protocol. Briefly, endometrial and cervical tissues
were ground using a mortar and pestle under liquid nitro-
gen. The ground tissue was transferred to tubes containing
appropriate amounts of TRIzol reagent and homogenized
using a Brinkmann homogenizer. The mixture was
allowed to set for 5–10 min followed by the addition of
appropriate amount of chloroform. This mixture was
shaken vigorously and centrifuged at 8,000 × g for 30 min.
Slot blot analyses of total RNA from endometrial normal (EN) and tumors (EA) tissues using mucin MUC1 cDNA probe Figure 1
Slot blot analyses of total RNA from endometrial normal (EN) and tumors (EA) tissues using mucin MUC1 cDNA probe. Each 
graph is representative of three experimental replicates. Data normalized using β-actin as described in Methods.
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The aqueous layer was collected and the RNA precipitated
using isopropanol. The RNA pellet was washed using 70%
alcohol and dissolved in RNase free water. To determine
the quality of extracted RNA, the dissolved samples were
elecrophoresed on 1% formaldehyde-agarose gels to
check the integrity of 18s and 28s bands. Samples with
OD 260/280 greater than 1.50 were used in the study.
Slot blot analyses
Total RNA (10 µg) extracted from tissues was blotted
directly onto nylon membranes using a Hoefer PR 648
slot blot manifold (Amersham Biosciences, San Francisco,
CA). The membranes were pre-hybridized in 5× SSPE, 5×
Denhardt's solution, 0.5% SDS, 50% formamide and 40
µg/ml salmon sperm DNA for 12 h at 42°C. The cDNA
probes (MUC1, MUC2, MUC5B, MUC5AC, MUC8 and β-
actin) were labeled by the random priming technique
using DECAprime II kit (Ambion, Austin, TX). Hybridiza-
tion of 32P-labeled cDNA probes was carried out at 42°C
for 14–16 h. After hybridization, membranes were
washed twice in 2× SSC and 0.1% SDS for 10 min. at
room temperature, followed by two additional washes for
20 min at 65°C in 1× SSC and 0.1% SDS solution. The
membranes were subsequently exposed to Kodak X-Omat
AR films at -70°C. The films were scanned using a Per-
sonal SI Densitometer (Molecular Dynamics, Sunnyvale,
Slot blot analyses of total RNA from endometrial normal (EN) and tumors (EA) tissues using mucin MUC5B cDNA probe Figure 2
Slot blot analyses of total RNA from endometrial normal (EN) and tumors (EA) tissues using mucin MUC5B cDNA probe. The 
data was normalized using β-actin as described in Methods section.
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CA). Following exposure, the membranes were stripped
with 0.5% SDS and re-probed with β-actin. Densitromet-
ric units were calculated for each sample after normaliza-
tion of the readings with corresponding densitrometric
readings obtained using β-actin cDNA probe. The hybrid-
ization experiments on total RNA from the tissues was
performed in triplicate for statistical analyses.
Source of mucin cDNA probes
The cDNA probes used in the study were designed to
exclude the VNTR regions of the studied MUC genes. This
step was deemed essential to avoid the differences in the
numbers of tandem repeats commonly associated with
mucins among different individuals. The cDNA probes for
MUC1 (~500 bp) was kindly provided by Dr. Sandra Gen-
dler [30], MUC2 (~450 bp) was a kind gift from Dr. James
Gum [31], MUC5AC (~800 bp) and MUC5B (~340 bp)
were generated in the laboratory using specific primers to
the published sequences. Earlier, MUC8 cDNA probe (1.4
kb) sequence has been reported from our laboratory [5].
This sequence was used in this study to develop a non-
repeat 195 bp MUC8 cDNA probe. A 1.1 kb cDNA probe
specific for β-actin was used for the analyses of house-
keeping gene.
Slot blot analyses of total RNA from endometrial normal (EN) and tumors (EA) tissues using mucin MUC8 cDNA probe Figure 3
Slot blot analyses of total RNA from endometrial normal (EN) and tumors (EA) tissues using mucin MUC8 cDNA probe. The 
data was normalized using β-actin. Note: Larger scale used, indicative of higher expression of MUC8.
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Reverse Transcription and Polymerase Chain Reaction 
(RT-PCR)
Five micrograms of total RNA was reverse transcribed to
cDNA by 200 units Superscript II reverse transcriptase
(Life Technologies). The reaction mixture was then treated
with 2U RNaseH at 37°C for 20 min and stored at -20°C.
Twenty percent of the first strand cDNA was used for the
PCR amplification. Primers and annealing temperatures
used for RT-PCR are summarized in Table 1.
Statistical analyses
The data obtained from slot blot analyses of MUC genes
in both normal and tumor tissues were subjected to para-
metric statistical analysis using SAS software (SAS Insti-
tute, Cary, NC). Two tailed unequal variance student t test
was used to establish statistical significance. A p value of
less than 0.05 was considered significant.
Results
Quantitation of mucin gene expression in endometrial 
tissues
As shown in Fig. 1MUC1  expression was significantly
lower in the normal endometrium as compared to the
endometrial adenocarcinomas (p = 0.001). Expression of
MUC5B followed a similar pattern with higher expression
observed in 8 out of 13 endometrial tumor tissues studied
over normal tissues (Fig. 2). The differences in MUC5B
levels between the cancerous and non-cancerous endome-
trial samples was significant (p = 0.006). On the other
hand, expression of MUC8 was high in all endometrial tis-
Analyses of total RNA from cervical normal (CN) and tumors (CA) tissues using MUC1 cDNA probe Figure 4
Analyses of total RNA from cervical normal (CN) and tumors (CA) tissues using MUC1 cDNA probe. Data was normalized 
using β-actin cDNA probe.
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sues, with the expression in endometrial adenocarcino-
mas being significantly higher than the normal
endometrium (p = 0.003) (Fig. 3). The box plot analyses
showing the relationship between MUC gene expression
in endometrial tumor and normal tissues are depicted in
Fig. 7. No appreciable expression of MUC2 and MUC5AC
in normal and tumor tissues was detected by slot blot
analyses.
Quantitation of mucin gene expression in cervical tissues
Levels of expression of MUC1 in cervical carcinomas were
significantly different from normal cervical tissue. (p =
0.002) (Fig. 4). While the expression of MUC5B, was
higher than MUC1 in normal cervical tissues, no statistical
significance was observed in MUC5B levels between nor-
mal and cancerous cervical tissues (p = 0.14) (Fig. 5). The
expression MUC8 mRNA, were high in all cervical tissues
with no statistical difference observed in expression
between cancerous and non-cancerous tissues (p = 0.5).
Also, box plots depicting MUC gene expression in cervical
tumor and normal tissues are illustrated in Fig. 8.
Discussion
This study is primarily focused on the quantitating the
expression of five mucin genes, namely, MUC1, MUC2,
MUC5AC,  MUC5B  and  MUC8  in normal human
endometrial and cervical tissues and respective tumors.
Studies in tumors have suggested that mucins are aber-
rantly expressed in cancerous conditions. In the present
investigation we observed that of the five MUC  genes
Analyses of total RNA from cervical normal (CN) and tumors (CA) tissues using MUC5B cDNA probe Figure 5
Analyses of total RNA from cervical normal (CN) and tumors (CA) tissues using MUC5B cDNA probe. Data was normalized 
using β-actin as described in Methods section.
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studied,  MUC1,  MUC5B  and  MUC8  were expressed at
higher levels than MUC2 and MUC5AC in endometrial
and cervical tissues. Similar studies by other investigators
on endocervical tissues have revealed MUCs 1, 4, 5AC, 5B
and 6 were expressed at high levels with very low expres-
sion of MUCs 2, 3 and 7 [26]. However, a follow-up study
to this work quantifying the expression of these MUC
genes in normal endocervical epithelium revealed that
MUC4  and  MUC5B  were predominantly expressed as
compared to MUC6 and MUC5AC [32]. While acknowl-
edging the variations in the analyzed tissue types, it
appears that expression patterns of MUC2 and MUC5AC
genes in this study are broadly confirmatory with earlier
reports.
Human endometrial epithelium undergoes progesterone-
modulated differentiation during menstrual cycle [33,34].
The qualitative and quantitative changes in the secretion
of the endometrium are associated with the proliferation
of glandular epithelium with increased golgi and secretory
apparatus [35]. Accordingly, mucin secretions and MUC
gene expression of the female reproductive tissues are
dependant on the stage of the menstrual cycle[36]. Earlier
studies have shown that MUC1 expression in endometrial
tissues is at the highest in early to mid secretory phases
[37]. To minimize the ambiguity of elevated MUC gene
expression due to menstrual cycle, the tissues studied in
the present investigation are from patients in either prolif-
erative or late secretory phases. Mucin gene regulation and
expression has been associated with the effects of immune
Analyses of total RNA from cervical normal (CN) and tumors (CA) using MUC8 cDNA probe Figure 6
Analyses of total RNA from cervical normal (CN) and tumors (CA) using MUC8 cDNA probe. Data was normalized using β-
actin as described in Methods section. Note: Larger scale used, indicative of higher expression of MUC8.
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cell derived inflammatory mediators [38] and bacterial
endotoxins [39] on the secretory epithelium in various
chronic diseases states of human body. However, in this
study the pathology reports of the obtained tissues indi-
cate no inflammation or infection thus minimizing the
effect of these mediators on overall results of this study.
MUC1, a trans-membrane mucin, has been studied exten-
sively in the female reproductive tract and is expressed in
the endometrium. It plays an important role during
implantation and maintenance of the embryo [40,41].
Our studies revealed high MUC1 levels in endometrial
adenocarcinomas and cervical carcinomas when com-
pared to the normal endometrial and cervical tissues.
These results are in accord with studies where MUC1 up-
regulation was reported in variety of carcinomas including
pancreas[42], breast[43], stomach[44], colon rectum [45]
and lung [46].
In addition, to altered gene regulation patterns in cancer-
ous conditions, it is reported that alterations may exist in
the carbohydrate structures attached to the protein back-
bone or in the protein backbone itself. In MUC1,
alteration in glycosylation patterns leads to tumor-specific
peptide epitopes that are exposed in cancerous cells [47].
In breast cancer tissue, an alternatively spliced form of
MUC1, which is completely devoid of repeats was
observed [14]. This variant of MUC1 was not expressed in
adjacent normal breast tissue. Such studies and others
indicate the importance of mucins as tumor markers for
Box plots showing the relationship between MUC gene expression in endometrial tumors tissues (EA) and normal tissues (EN) Figure 7
Box plots showing the relationship between MUC gene expression in endometrial tumors tissues (EA) and normal tissues (EN). 
(a) MUC1 (b) MUC5B (c) MUC8.
MUC1 MUC5B MUC8BMC Cancer 2005, 5:124 http://www.biomedcentral.com/1471-2407/5/124
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diagnostic as well as for therapeutic purposes. For exam-
ple, in ovarian cancers the CA125 antigen is routinely
used to monitor the progress of patients. Recently, inves-
tigators found that the CA125 antigen does indeed belong
to the mucin family of genes and its core was identified
and designated as MUC16 [48].
Our laboratory has previously reported a novel mucin
gene MUC8 from human normal tracheal tissue [5] and
here we have studied the expression of MUC8 in human
normal as well as cancerous endometrial and cervical tis-
sues. Our earlier studies demonstrated that MUC8  is
expressed in the male and female reproductive tract [29].
The present work has led us to believe that MUC8 is a
major mucin expressed in the female reproductive tract.
Levels of MUC8 are significantly higher in the endome-
trial adenocarcinomas as compared to the normal
endometrium. Although the expression of MUC8 was very
high in the cervical tissues, no difference in expression was
observed among the cancerous and non-cancerous
tissues. In the context of MUC gene expression, this is the
first study reporting differential expression of MUC8 and
MUC5B in cervical and endometrial tissues.
One significant conclusion that can be drawn from this
study is that mucin genes, MUC1, MUC5B and MUC8 are
all up-regulated in endometrial adenocarcinomas. Fur-
thermore,  MUC2  and  MUC5AC  were found to be
expressed at extremely low levels in the endometrial and
cervical tissues studied. In conclusion, this study provides
Box plots showing the relationship between MUC gene expression in cervical tumors tissues (CA) and normal tissues (CN) Figure 8
Box plots showing the relationship between MUC gene expression in cervical tumors tissues (CA) and normal tissues (CN). (a) 
MUC1 (b) MUC5B (c) MUC8.
MUC1 MUC5B MUC8BMC Cancer 2005, 5:124 http://www.biomedcentral.com/1471-2407/5/124
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significant information on mucin genes in the female
reproductive tract and attempts to understand if there are
disease-related changes that mucin genes may undergo in
endometrial and cervical carcinomas.
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